[HTML][HTML] Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non–small cell lung cancer with activating EGFR gene mutations …
E Ichihara, K Hotta, N Nogami, S Kuyama… - Journal of Thoracic …, 2015 - Elsevier
Purpose Whether bevacizumab enhances the effect of the epidermal growth factor receptor
(EGFR) inhibitor gefitinib on EGFR mutant non–small cell lung cancers (NSCLCs) remains …
(EGFR) inhibitor gefitinib on EGFR mutant non–small cell lung cancers (NSCLCs) remains …
[引用][C] Phase II Trial of Gefitinib in Combination with Bevacizumab as First-Line Therapy for Advanced Non–Small Cell Lung Cancer with Activating EGFR Gene …
E Ichihara, K Hotta, N Nogami, S Kuyama… - Journal of Thoracic …, 2015 - cir.nii.ac.jp
Phase II Trial of Gefitinib in Combination with Bevacizumab as First-Line Therapy for Advanced
Non–Small Cell Lung Cancer with Activating EGFR Gene Mutations: The Okayama Lung …
Non–Small Cell Lung Cancer with Activating EGFR Gene Mutations: The Okayama Lung …
Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: The …
E Ichihara, K Hotta, N Nogami… - Journal of …, 2015 - okayama.elsevierpure.com
Purpose: Whether bevacizumab enhances the effect of the epidermal growth factor receptor
(EGFR) inhibitor gefitinib on EGFR mutant non-small cell lung cancers (NSCLCs) remains …
(EGFR) inhibitor gefitinib on EGFR mutant non-small cell lung cancers (NSCLCs) remains …
[PDF][PDF] A Phase II Trial of Gefitinib in Combination with Bevacizumab as First-Line Therapy for Advanced Non–Small Cell Lung Cancer with Activating EGFR Gene …
KH Kirin, E Chugai Pharma, L Takeda… - Journal of Thoracic …, 2015 - scholar.archive.org
Purpose: Whether bevacizumab enhances the effect of the epidermal growth factor receptor
(EGFR) inhibitor gefitinib on EGFR mutant non–small cell lung cancers (NSCLCs) remains …
(EGFR) inhibitor gefitinib on EGFR mutant non–small cell lung cancers (NSCLCs) remains …
[HTML][HTML] Phase II Trial of Gefitinib in Combination with Bevacizumab as First-Line Therapy for Advanced Non–Small Cell Lung Cancer with Activating EGFR Gene …
E Ichihara, K Hotta, N Nogami, S Kuyama… - Journal of Thoracic …, 2015 - jto.org
Purpose Whether bevacizumab enhances the effect of the epidermal growth factor receptor
(EGFR) inhibitor gefitinib on EGFR mutant non–small cell lung cancers (NSCLCs) remains …
(EGFR) inhibitor gefitinib on EGFR mutant non–small cell lung cancers (NSCLCs) remains …
Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the …
E Ichihara, K Hotta, N Nogami, S Kuyama… - Journal of Thoracic …, 2015 - europepmc.org
Purpose Whether bevacizumab enhances the effect of the epidermal growth factor receptor
(EGFR) inhibitor gefitinib on EGFR mutant non-small cell lung cancers (NSCLCs) remains …
(EGFR) inhibitor gefitinib on EGFR mutant non-small cell lung cancers (NSCLCs) remains …
Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the …
E Ichihara, K Hotta, N Nogami… - Journal of thoracic …, 2015 - pubmed.ncbi.nlm.nih.gov
Purpose Whether bevacizumab enhances the effect of the epidermal growth factor receptor
(EGFR) inhibitor gefitinib on EGFR mutant non-small cell lung cancers (NSCLCs) remains …
(EGFR) inhibitor gefitinib on EGFR mutant non-small cell lung cancers (NSCLCs) remains …
[PDF][PDF] A Phase II Trial of Gefitinib in Combination with Bevacizumab as First-Line Therapy for Advanced Non–Small Cell Lung Cancer with Activating EGFR Gene …
KH Kirin, E Chugai Pharma, L Takeda… - Journal of Thoracic …, 2015 - academia.edu
Purpose: Whether bevacizumab enhances the effect of the epidermal growth factor receptor
(EGFR) inhibitor gefitinib on EGFR mutant non–small cell lung cancers (NSCLCs) remains …
(EGFR) inhibitor gefitinib on EGFR mutant non–small cell lung cancers (NSCLCs) remains …
[引用][C] Phase II trial of gefitinib in combination with bevacizumab as first‐line therapy for advanced non‐small‐cell lung cancer with activating EGFR gene mutations …
E Ichihara - Lung Cancer, 2015 - cir.nii.ac.jp
Phase II trial of gefitinib in combination with bevacizumab as first‐line therapy for advanced
non‐small‐cell lung cancer with activating EGFR gene mutations: The Okayama Lung Cancer …
non‐small‐cell lung cancer with activating EGFR gene mutations: The Okayama Lung Cancer …
Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: The …
E Ichihara, K Hotta, N Nogami… - Journal of …, 2015 - okayama.elsevierpure.com
Purpose: Whether bevacizumab enhances the effect of the epidermal growth factor receptor
(EGFR) inhibitor gefitinib on EGFR mutant non-small cell lung cancers (NSCLCs) remains …
(EGFR) inhibitor gefitinib on EGFR mutant non-small cell lung cancers (NSCLCs) remains …